Sovaldi price worries states

Share this article:

Gilead's hepatitis C drug Sovaldi is giving Medicaid and private insurers a headache. Reuters reports that several insurers are talking with state agencies about how to handle Medicaid payments for a treatment that costs around $84,000 per person.

Reuters notes that this can also be just a starting price and that “many doctors are requesting a $150,000 combination of Sovaldi (sofosbuvir) and Olysio (simeprevir).”

This too, is a starting point of sorts: Harvard Medical School's Camilla Graham told Reuters that a cumulative number would probably hover around the $200 billion mark to treat two-thirds of hepatitis C patients at around $100,000 each.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters